share_log

Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2024 Financial Results

Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2024 Financial Results

吉利德科學 | 8-K:吉利德科學公佈2024年第二季財務業績
美股SEC公告 ·  2024/08/09 04:39

Moomoo AI 已提取核心訊息

Gilead Sciences reported Q2 2024 total revenue of $7.0 billion, up 5% year-over-year, with product sales excluding Veklury increasing 6% to $6.7 billion. HIV sales grew 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenue rose 15% to $841 million, with Trodelvy sales up 23% to $320 million.Operating income reached $2.6 billion, with GAAP diluted EPS of $1.29 compared to $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues. Cash and equivalents stood at $2.8 billion as of June 30, down from $8.4 billion at year-end 2023, primarily due to the $3.9 billion CymaBay acquisition.The company maintained its full-year 2024 product sales guidance of $27.1-27.5 billion, with product sales excluding Veklury projected at $25.8-26.2 billion. The non-GAAP EPS guidance was raised to $3.60-3.90 from the previous $3.45-3.85 range.
Gilead Sciences reported Q2 2024 total revenue of $7.0 billion, up 5% year-over-year, with product sales excluding Veklury increasing 6% to $6.7 billion. HIV sales grew 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenue rose 15% to $841 million, with Trodelvy sales up 23% to $320 million.Operating income reached $2.6 billion, with GAAP diluted EPS of $1.29 compared to $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues. Cash and equivalents stood at $2.8 billion as of June 30, down from $8.4 billion at year-end 2023, primarily due to the $3.9 billion CymaBay acquisition.The company maintained its full-year 2024 product sales guidance of $27.1-27.5 billion, with product sales excluding Veklury projected at $25.8-26.2 billion. The non-GAAP EPS guidance was raised to $3.60-3.90 from the previous $3.45-3.85 range.
吉利德科學報告稱,2024年第二季度總營業收入爲70億美金,同比上升5%,剔除Veklury的產品銷售增長6%,達到67億美金。HIV銷售增長3%,達到47億美金,主要受益於Biktarvy增長8%,達到32億美金。腫瘤業務營業收入增長15%,達到84100萬美金,Trodelvy銷售增長23%,達到32000萬美金。營業收入達到26億美金,GAAP攤薄後每股收益爲1.29美金,相較於2023年第二季度的0.83美金有所提升。改善的原因是營業費用降低和營業收入提高。截止6月30日,公司現金及現金等價物爲28億美金,低於2023年年底的84億美金,主要是因爲39億美金的CymaBay收購。公司維持2024年全年的產品銷售指導爲271-275億美金,剔除Veklury的產品銷售預計爲258-262億美金。非GAAP每股收益指導從之前的3.45-3.85區間上調至3.60-3.90。
吉利德科學報告稱,2024年第二季度總營業收入爲70億美金,同比上升5%,剔除Veklury的產品銷售增長6%,達到67億美金。HIV銷售增長3%,達到47億美金,主要受益於Biktarvy增長8%,達到32億美金。腫瘤業務營業收入增長15%,達到84100萬美金,Trodelvy銷售增長23%,達到32000萬美金。營業收入達到26億美金,GAAP攤薄後每股收益爲1.29美金,相較於2023年第二季度的0.83美金有所提升。改善的原因是營業費用降低和營業收入提高。截止6月30日,公司現金及現金等價物爲28億美金,低於2023年年底的84億美金,主要是因爲39億美金的CymaBay收購。公司維持2024年全年的產品銷售指導爲271-275億美金,剔除Veklury的產品銷售預計爲258-262億美金。非GAAP每股收益指導從之前的3.45-3.85區間上調至3.60-3.90。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息